Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iadademstat, Venetoclax, and Azacitidine in Treatment Naive AML
NCT06514261Phase 1Suspended
- Sponsor
- National Cancer Institute
- Start
- Dec 2024
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iadademstat in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Primary endpoints: Incidence of dose limiting toxicity and Incidence of Adverse Events. Started Dec 2024; status: suspended.
02
Drugs
iadademstat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06514261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06514261.